Terms: = Lung cancer AND MYH9, P35579, 4627, ENSG00000100345, DFNA17
26 results:
1. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to myh9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
2. LAMC2 mitigates ER stress by enhancing ER-mitochondria interaction via binding to myh9 and MYH10.
Tong D; Zhou J; Zhou J; Wang X; Gao B; Rui X; Liu L; Chen Q; Huang C
Cancer Gene Ther; 2024 Jan; 31(1):43-57. PubMed ID: 37891404
[TBL] [Abstract] [Full Text] [Related]
3. DNAJA4 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma via PSMD2-mediated myh9 degradation.
Zhang Q; Feng P; Zhu XH; Zhou SQ; Ye ML; Yang XJ; Gong S; Huang SY; Tan XR; He SW; Li YQ
Cell Death Dis; 2023 Oct; 14(10):697. PubMed ID: 37875476
[TBL] [Abstract] [Full Text] [Related]
4. [High expression of myh9 inhibits apoptosis of non-small cell lung cancer cells through activating the AKT/c-Myc pathway].
Liu F; Peng L; Xi J
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Apr; 43(4):527-536. PubMed ID: 37202187
[TBL] [Abstract] [Full Text] [Related]
5. SAMD9 Promotes Postoperative Recurrence of Esophageal Squamous Cell Carcinoma by Stimulating myh9-Mediated GSK3β/β-Catenin Signaling.
Li Q; Luo H; Dai FQ; Wang RT; Fan XQ; Luo YY; Deng MS; Wang Y; Long T; Guo W; Xu B; Xu CX; Jin H
Adv Sci (Weinh); 2023 Apr; 10(11):e2203573. PubMed ID: 36757050
[TBL] [Abstract] [Full Text] [Related]
6. Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1-FGL1-myh9 axis.
Tang XY; Xiong YL; Zhao YB; Yang J; Shi AP; Zheng KF; Liu YJ; Shu C; Jiang T; Ma N; Zhao JB
Front Immunol; 2022; 13():1014053. PubMed ID: 36268014
[TBL] [Abstract] [Full Text] [Related]
7. ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating β-catenin/c-Jun/myh9/USP7/c-Myc axis.
Hou R; Li Y; Luo X; Zhang W; Yang H; Zhang Y; Liu J; Liu S; Han S; Liu C; Huang Y; Liu Z; Li A; Fang W
Int J Biol Sci; 2022; 18(6):2553-2567. PubMed ID: 35414777
[TBL] [Abstract] [Full Text] [Related]
8. The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress myh9-mediated c-Myc deubiquitination in lung adenocarcinoma.
Liu JH; Yang HL; Deng ST; Hu Z; Chen WF; Yan WW; Hou RT; Li YH; Xian RT; Xie YY; Su Y; Wu LY; Xu P; Zhu ZB; Liu X; Deng YL; Wang YB; Liu Z; Fang WY
Acta Pharmacol Sin; 2022 Oct; 43(10):2687-2695. PubMed ID: 35296779
[TBL] [Abstract] [Full Text] [Related]
9. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/myh9 axis.
Xu Y; Zhao R; Wang H; Jiang J; Wang Z; Wang J; Zhang W; Li M
J BUON; 2021; 26(5):1850-1861. PubMed ID: 34761592
[TBL] [Abstract] [Full Text] [Related]
10. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract] [Full Text] [Related]
11. myh9 promotes cell metastasis
Yang B; Liu H; Bi Y; Cheng C; Li G; Kong P; Zhang L; Shi R; Zhang Y; Zhang R; Cheng X
Int J Med Sci; 2020; 17(13):2013-2023. PubMed ID: 32788880
[TBL] [Abstract] [Full Text] [Related]
12. Nuclear myh9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis.
Ye G; Yang Q; Lei X; Zhu X; Li F; He J; Chen H; Ling R; Zhang H; Lin T; Liang Z; Liang Y; Huang H; Guo W; Deng H; Liu H; Hu Y; Yu J; Li G
Theranostics; 2020; 10(17):7545-7560. PubMed ID: 32685004
[No Abstract] [Full Text] [Related]
13. Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study.
Walls GM; McConnell L; McAleese J; Murray P; Lynch TB; Savage K; Hanna GG; de Castro DG
Radiat Oncol; 2020 May; 15(1):132. PubMed ID: 32471446
[TBL] [Abstract] [Full Text] [Related]
14. MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma.
Zhou W; Liu Y; Gao Y; Cheng Y; Chang R; Li X; Zhou Y; Wang S; Liang L; Duan C; Zhang C
Cancer Lett; 2020 Jul; 483():75-86. PubMed ID: 32360180
[TBL] [Abstract] [Full Text] [Related]
15. PTP1B up-regulates EGFR expression by dephosphorylating myh9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma.
Pan BQ; Xie ZH; Hao JJ; Zhang Y; Xu X; Cai Y; Wang MR
Biochem Biophys Res Commun; 2020 Jan; 522(1):53-60. PubMed ID: 31735331
[TBL] [Abstract] [Full Text] [Related]
16. myh9: Structure, functions and role of non-muscle myosin IIA in human disease.
Pecci A; Ma X; Savoia A; Adelstein RS
Gene; 2018 Jul; 664():152-167. PubMed ID: 29679756
[TBL] [Abstract] [Full Text] [Related]
17. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
De Rienzo A; Archer MA; Yeap BY; Dao N; Sciaranghella D; Sideris AC; Zheng Y; Holman AG; Wang YE; Dal Cin PS; Fletcher JA; Rubio R; Croft L; Quackenbush J; Sugarbaker PE; Munir KJ; Battilana JR; Gustafson CE; Chirieac LR; Ching SM; Wong J; Tay LC; Rudd S; Hercus R; Sugarbaker DJ; Richards WG; Bueno R
Cancer Res; 2016 Jan; 76(2):319-28. PubMed ID: 26554828
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic significance of myh9 expression in resected non-small cell lung cancer.
Katono K; Sato Y; Jiang SX; Kobayashi M; Nagashio R; Ryuge S; Fukuda E; Goshima N; Satoh Y; Saegusa M; Masuda N
PLoS One; 2015; 10(3):e0121460. PubMed ID: 25826333
[TBL] [Abstract] [Full Text] [Related]
19. The role of vertebrate nonmuscle Myosin II in development and human disease.
Ma X; Adelstein RS
Bioarchitecture; 2014; 4(3):88-102. PubMed ID: 25098841
[TBL] [Abstract] [Full Text] [Related]
20. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.
Schramek D; Sendoel A; Segal JP; Beronja S; Heller E; Oristian D; Reva B; Fuchs E
Science; 2014 Jan; 343(6168):309-13. PubMed ID: 24436421
[TBL] [Abstract] [Full Text] [Related]
[Next]
